Ataxia Biologics is a clinical-stage biotechnology company that is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. Avaxia’s proprietary oral antibody platform makes direct delivery of antibodies to the GI tract possible by overcoming some of the traditional limitations of antibody therapeutics. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia is developing gut-targeted therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome, and oral mucositis.
Total raised: $24.1M
Investors 3
Funding Rounds 4
| Date | Series | Amount | Investors |
| 07.06.2013 | Series B | $11.4M | - |
| 18.12.2012 | Series B | $6.4M | - |
| 14.02.2012 | Series A | $4.1M | - |
| 10.11.2011 | Series A | $2.2M | - |
Mentions in press and media 10
| Date | Title | Description |
| 07.06.2013 | Avaxia Biologics Completes $11.4M Series B Financing | Avaxia Biologics, a Lexington, MA-based biopharmaceutical company, completed a $11.4m Series B financing. The round was led by Cherrystone Angels and Golden Seeds, with participation from new investors AbbVie Inc., Ariel Southeast Angel Par... |
| 07.06.2013 | Avaxia Biologics Closes $11.4M in Series B | LEXINGTON, MA, Clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company closed its Series B financing with total proceeds of $11.4 million. >> Click here for more funding data ... |
| 18.12.2012 | Avaxia Biologics Raises $6.4M in Series B | LEXINGTON, MA, Clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company raised $6.4 million in a Series B financing. >> Click here for more funding data on Avaxia Biologics &g... |
| 18.12.2012 | Avaxia Biologics Raises $6.4M in Series B Financing | Avaxia Biologics, Inc., a Lexington, MA-based clinical-stage biopharmaceutical company developing gut-targeted therapeutics, raised $6.4m in Series B financing. The round was led by existing investor Cherrystone Angels and new investor Gold... |
| 28.11.2012 | Avaxia cleared to start human trials of oral antibody for Crohn’s disease, ulcerative colitis | So, rather than being injected into the bloodstream, the drug goes right to where inflammation occurs in the GI tract. Existing TNF inhibitors are distributed throughout the body and may cause side effects associated with immunosuppression ... |
| 14.02.2012 | Avaxia Biologics Completes $4.1M Series A Financing | Avaxia Biologics, Inc., a Lexington, MA-based biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, completed a $4.1m Series A angel financing. The round was led by Cherrystone Angels of Providen... |
| 14.02.2012 | Avaxia Biologics Closes $4.1M Series A | LEXINGTON, MA, Privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced that the company completed its $4.1 million Series A angel-led financing. >> Click here for ... |
| 10.11.2011 | Avaxia Biologics Raises $2.2M in Series A Financing | Avaxia Biologics, Inc., a Lexington, MA-based biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, completed a $2.2m first close of a Series A financing. The round was led by Cherrystone Angels,... |
| 25.03.2008 | Early Stage Life Sciences Pitches—12 Firms Looking for Funding | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Whether it’s to learn about new approaches to cancer treatment, better ways to harvest stem cells, or cutting edge arthritis and anxiety drugs, I always have a good time at ev... |
| - | Avaxia cleared to start human trials of oral antibody for Crohn’s disease, ulcerative colitis | A 7-year-old pharmaceutical company that’s developed a new way to create and deliver an old kind of drug is making the critical transition to the clinical stage as it prepares to take its drug for Crohn’s disease and ulcerative colitis into... |